Saturday, April 20 2019

VietNamNews

Bayer Pharmaceuticals Reports Eighth Straight Year of Growth in Asia Pacific

Update: April, 01/2019 - 09:00
Claus Zieler, Senior Vice President and Head of Commercial Operations, Bayer Pharmaceuticals Division Asia/Pacific outlined Bayer Pharmaceuticals’ strong performance in Asia/Pacific in 2018 and outlook for 2019. — VNS Photo
Viet Nam News

SINGAPORE — There is a strong demand for Bayer’s innovative medicines in Asia Pacific which has driven the growth of its pharmaceutical business in the region, Claus Zieler, senior vice president and head of commercial operations, Bayer Pharmaceuticals Division Asia Pacific, said.

In 2018 the company’s key products like oral anticoagulant medicines, eye medicines and oral cancer drugs continued to be well received by doctors and patients in the Asia Pacific, he said.

“Our strong performance year after year speaks of the strong demand for our innovative medicines as they deliver significant benefits to patients battling serious diseases such as cardiovascular diseases, cancer and eye diseases related to ageing and diabetes. We will continue to bring new and better treatments to patients in the region and build more collaboration with external partners here.”

Bayer reported that as  of 2018 nearly 48 million packs had been delivered to patients in the Asia Pacific for blood clot prevention and treatment for several indications across the venous and arterial thromboembolic (VAT) space and about 3.5 million doses have been administered to patients in the region for treatment of retinal disorders including wet age-related macular degeneration and diabetic macular. Nearly 1.4 million packs were delivered to patients in the region for treatment of late-stage liver cancer, advanced kidney cancer and differentiated thyroid cancer from 2010 to 2018.

Year 2018 was another one of robust growth, the company said, revealing that the region’s sales grew 7.3 per cent to over 5.2 billion euros (US$5.6 billion), marking the eighth consecutive year of growth for its pharmaceuticals sales in the region.

The region contributed more than 30 per cent to the division’s global sales and continued to be the fastest growing reporting region for Bayer’s pharmaceutical business.

The company’s pharmaceutical business was again ranked one of the fastest growing amongst top multinational pharmaceutical companies in the Asia Pacific in 2018 by global health intelligence agency IQVIA.

This year the company targets global pharmaceuticals sales growth of around 4 per cent.

The  outlook for the Asia Pacific region remains positive, with IQVIA projecting an average growth rate of 3.6 per cent for the pharmaceutical markets in the region from 2019 to 2022.

More investment in R&D

In 2018 Bayer invested around 3 billion euros ($3.4 billion) in research and development of new drugs globally.

Its pharmaceuticals pipeline is well stocked, the company announced, with about 50 development projects.

Of them, many might have the potential to treat various types of cancers, diabetic kidney disease, and chronic heart failure which represent areas of high medical needs for the region’s ageing populations.

The Asia Pacific is strongly represented in the company’s clinical development activities and real-world studies.

In 2018 there were 54 ongoing clinical trials and 69 real-world studies in the region. Of them, 22 of the former and four of the latter are in Singapore, the company said.

“We are working hard to address the healthcare burden in our region by bringing new and better treatments to patients. By involving Asia Pacific patients in our clinical development activities, we can provide patients with earlier access to our innovative medicines.”

Dr Chuan Kit Foo, head of medical affairs, Bayer Pharmaceuticals Division Asia Pacific, said: “Even after the launch of our new products, we continue to conduct real-world studies, to provide robust insights into the use of our medicines in daily clinical settings to help doctors and patients make informed decisions about their treatments.”

The company has continued to expand its collaboration activities in the region. These range from strategic research alliances with the medical and scientific communities to open innovation platforms involving entrepreneurs, start-ups and the wider public.

Recently Bayer, in partnership with NUS Enterprise, the entrepreneurial arm of the National University of Singapore, announced the Healthy Hearts, Healthy Aging initiative to drive adoption of innovation in cardiovascular diseases prevention in Asia Pacific.

This initiative, among others, is aimed at bringing together healthcare experts, policy makers, innovators, academia, non-governmental organizations, and corporations to examine the role of health innovations in preventing serious cardiovascular events such as strokes and heart attacks in seniors living with cardiovascular diseases.

The report will also gather recommendations on how different stakeholders can collaborate to enhance the adoption of health innovation in the long-term preventive care of cardiovascular patients. — VNS

 

Send Us Your Comments:

See also: